Schering AG of Germany says that net sales increased 7% to 3.58 billioneuros ($3.22 billion) for the first nine months of 2001 and net income improved 23% to 331 million euros. Operating profit, however, advanced just 4% to 494 million euros, reflecting investments in its new product launches both in the USA and Europe, the company notes.
The multiple sclerosis drug Betaferon/Betaseron (interferon beta-1b) continued to be Schering's largest-selling product, with turnover up 12% to 491 million euros for the six months. The firm notes that, in the USA, the success of Betaferon and the chronic lymphocytic leu-kemia drug Fludara (fludarabine), with sales up 22% at 100 million euros), enabled Schering to cushion the fall of Betapace (sotalol), turnover of which fell 49% to 77 million euros.
Strong start for Campath
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze